mash semaglutide targets molecular pathways beyond weight loss Novo Nordisk leads MASH therapeutic

Risk Factors Age over 50 Family history of colorectal cancer or polyps Inflammatory bowel disease (ulcerative colitis, Crohns) Diet high in red/processed meat Low fiber intake Obesity Smoking Alcohol use Genetic syndromes: Familial adenomatous polyposis (FAP) Lynch syndrome (HNPCC) Common Symptoms Early stages may be silent

GLP-1 is an incretin hormone and enterogastrone that stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and reduces the production of stomach acid serving as a physiological regulator of appetite and food intake

It positively impacts risk factors associated blood pressure and lipid profile

Persistent tiredness can signal undereating relative to your activity level, inadequate micronutrient intake (especially iron, B12, and magnesium), or an underlying condition unrelated to semaglutide

Jaensch, N., Corra, I